The company issued 19,818,972 shares at $0.29 per share.
Stem cell therapy developer Brainstorm Cell Therapeutics Ltd. (Bulletin Board:BCLI) has raised a gross $5.7 million in a secondary offering on Thursday. The company issued 19,818,972 shares at $0.29 per share, and warrants for the purchase of 14,864,229 shares at a strike price of $0.29 per share. The warrants are valid for 30 months.
Maxim Group LLC was the lead underwriter for the offering and Leader Underwriters (1993) Ltd. was the sub-agent.
Brainstorm's share price rose 1.7% on Friday to $0.29, giving a market cap of $37 million.
Published by Globes [online], Israel business news - www.globes-online.com - on July 22, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012